Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLC

Barlesi, F; Garon, EB; Kim, DW; Felip, E; Han, JY; Kim, JH; Ahn, MJ; Fidler, MJ; Gubens, MA; de Castro, G; Surmont, V; Li, Q; Deitz, AC; Lubiniecki, GM; Herbst, RS

Barlesi, F (reprint author), Aix Marseille Univ, AP HM, Multidisciplinary Oncol & Therapeut Innovat Dept, F-13015 Marseille, France.

JOURNAL OF THORACIC ONCOLOGY, 2019; 14 (5): 793

Abstract

Introduction: In the phase II/III KEYNOTE-010 study (ClinicalTrials.gov, NCT01905657), pembrolizumab significantly prolonged overall survival over doc......

Full Text Link


Links

期刊讨论 | 中国SCI论文 | 期刊主页 | 投稿经验 | 杂志官网 | 投稿链接 | 作者需知 | PMC链接 | Pubmed全文检索